Literature DB >> 24609871

DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation.

Alexander Sterzik1, Philipp M Paprottka1, Pamela Zengel2, Heidrun Hirner1, Svenja Roßpunt2, Ralf Eschbach1, Matthias Moser1, Lukas Havla3, Michael Ingrisch3, Brigitte Mack2, Maximilian F Reiser1, Konstantin Nikolaou1, Clemens C Cyran4.   

Abstract

BACKGROUND: Novel anti-angiogenic treatments are increasingly complementing established cancer therapy strategies in head and neck tumors. Contrast-enhanced magnetic resonance imaging (MRI) can be applied for early and non-invasive therapy monitoring by non-invasive quantitative assessment of tumor microcirculation as in vivo imaging biomarkers of therapy response.
PURPOSE: To monitor the anti-angiogenic effects of a novel combination therapy on experimental head and neck squamous cell carcinomas (HNSCC) with dynamic contrast-enhanced (DCE)-MRI.
MATERIAL AND METHODS: Athymic rats (n = 18) with subcutaneous HNSCC xenografts were investigated by DCE-MRI before and after 7 days of a daily triple therapy regimen combining the COX-II-inhibitor celecoxib, the matrix-metalloproteinase-inhibitor GM6001, and the uPA-inhibitor upamostat. Quantitative measurements of tumor blood flow (tBF), tumor blood volume (tBV), and permeability-surface area product (PS) were calculated and validated by immunohistochemistry.
RESULTS: Mean tBF and tBV in triple-therapy animals decreased significantly from day 0 to day 7 (tBF, 41.0 ± 14.2 to 20.4 ± 5.7 mL/100 mL/min; P < 0.01; tBV, 17.7 ± 3.9 to 7.5 ± 3.3%; P < 0.01). No significant effects on PS were observed in either group (P > 0.05). Immunohistochemical analysis showed a significantly lower tumor vascularity in the therapy group than in the control group (CD31), significantly fewer Ki-67+ proliferating tumor cells and significantly more Capase-3+ apoptotic tumor cells (P < 0.05). Significant (P < 0.05) correlations were observed between tBF/tBV and CD31 (tBF, r = 0.84; tBV, r = 0.70), tBV and Ki-67 (r = 0.62), as well as tBF and caspase-3 (r = -0.64).
CONCLUSION: DCE-MRI may be a suitable tool for the non-invasive monitoring of the anti-vascular effects of this innovative triple therapy regimen with potential for clinical translation. © The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Dynamic; GM6001; celecoxic; contrast-enhanced MRI; hypopharyngeal squamous cell carcinoma; therapy monitoring; upamostat

Mesh:

Substances:

Year:  2014        PMID: 24609871     DOI: 10.1177/0284185114527444

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  3 in total

1.  Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.

Authors:  Ralf S Eschbach; Wolfgang P Fendler; Philipp M Kazmierczak; Marcus Hacker; Axel Rominger; Janette Carlsen; Heidrun Hirner-Eppeneder; Jessica Schuster; Matthias Moser; Lukas Havla; Moritz J Schneider; Michael Ingrisch; Lukas Spaeth; Maximilian F Reiser; Konstantin Nikolaou; Clemens C Cyran
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

2.  Associations between Histogram Analysis Parameters Derived from DCE-MRI and Histopathological Features including Expression of EGFR, p16, VEGF, Hif1-alpha, and p53 in HNSCC.

Authors:  Hans Jonas Meyer; Leonard Leifels; Gordian Hamerla; Anne Kathrin Höhn; Alexey Surov
Journal:  Contrast Media Mol Imaging       Date:  2019-01-02       Impact factor: 3.161

3.  Clinical correlates of circulating cell-free DNA tumor fraction.

Authors:  Joerg Bredno; Jafi Lipson; Oliver Venn; Alexander M Aravanis; Arash Jamshidi
Journal:  PLoS One       Date:  2021-08-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.